IDH2 and glioma: To answer the question, a critical review is needed to evaluate if traditionally used risk factors for tumor progression and adverse outcomes truly capture the biology of the disease and correlate with outcomes of patients using the 2021 IDH-status-based glioma WHO CNS classification.